Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 28, 2022 16:05 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines to Present at the American Epilepsy Society 2022 Annual Meeting

BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
November 28, 2022 08:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines to Advance PRAX-562 Phase 2 Study in Pediatric Patients with Developmental and Epileptic Encephalopathies

BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
November 09, 2022 16:01 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2022 Financial Results

PRAX-944 Phase 2b Essential1 study topline results for essential tremor expected in 1Q23 PRAX-222 EMBRAVE study for SCN2A-DEE to initiate in 4Q22; topline results for initial dose cohort expected in...
November 07, 2022 09:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines to Present at Upcoming Investor Conferences

BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
September 21, 2022 09:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines to Present at Guggenheim Nantucket Therapeutics Conference

BOSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
September 20, 2022 08:30 ET | Source: Praxis Precision Medicines, Inc.

Invitae’s Real-World Ciitizen Data Utilized in Praxis Precision Medicines’ PRAX-222 IND Filing

SAN FRANCISCO and BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Invitae (NYSE: NVTA) and Praxis Precision Medicines, Inc. (NASDAQ: PRAX), today announced that real-world clinical insights from...
September 07, 2022 16:05 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines to Present at H.C. Wainwright 24th Annual Global Investment Conference

BOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
September 07, 2022 07:30 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines Provides Updates on Clinical Stage Pediatric Epilepsy Programs

BOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
August 08, 2022 16:01 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2022 Financial Results

PRAX-944 Phase 2b Essential1 Study topline results expected in 4Q22; primary endpoint updated to efficacy PRAX-562 Phase 1 study completed, confirming biomarker change and potential for wide...
August 03, 2022 09:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines to Present at 2022 Wedbush PacGrow Healthcare Conference

BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...